Stock Events

Stock Events

Axsome Therapeutics 

$129.81
159
-$9.80-7.02%Friday 03:21

Statistics

Day High
129.81
Day Low
129.81
52W High
252
52W Low
129.81
Volume
3
Avg. Volume
-
Mkt Cap
6.8B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 2Expected
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-1.26
-0.92
-0.59
-0.25
Expected EPS
-0.634252
Actual EPS
-0.25

Financials

-28.69%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
638.5MRevenue
-183.17MNet Income

Analyst Ratings

$266.23Average Price Target
The highest estimate is ⁦310.00⁩.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
92%
Hold
8%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AXSM.BOATS. It's not an investment recommendation.
NVIDIA
47
NVDA
Amazon
42
AMZN
Apple
38
AAPL
Microsoft
38
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.61B
Alkermes develops treatments for major depressive disorder and schizophrenia, overlapping with Axsome's CNS focus.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its Janssen Pharmaceuticals subsidiary, offers products that compete in the mental health space.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has a strong portfolio in psychiatric and neurological conditions, making it a direct competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical Industries has a broad CNS portfolio, including treatments for neurological conditions.
Novartis
NVS
Mkt Cap303.67B
Novartis offers medications for neurological conditions, competing in the same market as Axsome.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb has a diverse CNS portfolio, including treatments for psychiatric disorders.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a longstanding presence in the CNS and mental health market, competing with Axsome.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is involved in the development of CNS treatments, making it a competitor.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie, with its acquisition of Allergan, has expanded its CNS portfolio, directly competing with Axsome.

About

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Show More
CEO
ISIN
US05464T1043

Listings

MI
IT
1AXSM.MI
XETRA
DE
19X.XETRA
STU
DE
19X.STU
MX
MX
AZSM.MX

0 Comments

Share your thoughts

FAQs

What is Axsome Therapeutics stock price today?▼
The current price of AXSM.BOATS is $129.81 USD — it has decreased by -7.02% in the past 24 hours. Watch Axsome Therapeutics stock price performance more closely on the chart.
What is Axsome Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Axsome Therapeutics stocks are traded under the ticker AXSM.BOATS.
What is Axsome Therapeutics market cap?▼
Today Axsome Therapeutics has the market capitalization of 6.8B
When is the next Axsome Therapeutics earnings date?▼
Axsome Therapeutics is going to release the next earnings report on March 1, 2027.
What were Axsome Therapeutics earnings last quarter?▼
AXSM.BOATS earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.63 USD resulting in a +60.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Axsome Therapeutics revenue for the last year?▼
Axsome Therapeutics revenue for the last year amounts to 638.5M USD.
What is Axsome Therapeutics net income for the last year?▼
AXSM.BOATS net income for the last year is -183.17M USD.
In which sector is Axsome Therapeutics located?▼
Axsome Therapeutics operates in the Other sector.
When did Axsome Therapeutics complete a stock split?▼
Axsome Therapeutics has not had any recent stock splits.